AtheroGenics
Executive Summary
Aventis Pharmaceuticals VP-Respiratory & Rheumatoid Arthritis Disease Group Martin Wasserman, PhD, joins Atlanta-based AtheroGenics as VP-discovery research. Wasserman succeeds former Bristol-Myers Squibb Senior VP-Drug Discovery William Scott, PhD. Scott will remain on the board